Nuvation Bio Statistics
Total Valuation
Nuvation Bio has a market cap or net worth of $1.64 billion. The enterprise value is $1.33 billion.
Important Dates
The last earnings date was Monday, May 4, 2026, after market close.
| Earnings Date | May 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nuvation Bio has 348.20 million shares outstanding. The number of shares has increased by 15.09% in one year.
| Current Share Class | 347.20M |
| Shares Outstanding | 348.20M |
| Shares Change (YoY) | +15.09% |
| Shares Change (QoQ) | +0.87% |
| Owned by Insiders (%) | 24.30% |
| Owned by Institutions (%) | 64.59% |
| Float | 237.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.49 |
| Forward PS | 7.42 |
| PB Ratio | 5.14 |
| P/TBV Ratio | 5.32 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.28 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.44, with a Debt / Equity ratio of 0.68.
| Current Ratio | 7.44 |
| Quick Ratio | 7.04 |
| Debt / Equity | 0.68 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.38 |
Financial Efficiency
Return on equity (ROE) is -39.51% and return on invested capital (ROIC) is -19.40%.
| Return on Equity (ROE) | -39.51% |
| Return on Assets (ROA) | -17.02% |
| Return on Invested Capital (ROIC) | -19.40% |
| Return on Capital Employed (ROCE) | -28.30% |
| Weighted Average Cost of Capital (WACC) | 11.98% |
| Revenue Per Employee | $465,948 |
| Profits Per Employee | -$475,550 |
| Employee Count | 307 |
| Asset Turnover | 0.26 |
| Inventory Turnover | 1.66 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +132.51% in the last 52 weeks. The beta is 1.52, so Nuvation Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.52 |
| 52-Week Price Change | +132.51% |
| 50-Day Moving Average | 4.59 |
| 200-Day Moving Average | 5.12 |
| Relative Strength Index (RSI) | 51.89 |
| Average Volume (20 Days) | 4,917,185 |
Short Selling Information
The latest short interest is 50.62 million, so 14.54% of the outstanding shares have been sold short.
| Short Interest | 50.62M |
| Short Previous Month | 48.73M |
| Short % of Shares Out | 14.54% |
| Short % of Float | 21.30% |
| Short Ratio (days to cover) | 15.12 |
Income Statement
In the last 12 months, Nuvation Bio had revenue of $143.05 million and -$145.99 million in losses. Loss per share was -$0.42.
| Revenue | 143.05M |
| Gross Profit | 129.85M |
| Operating Income | -150.18M |
| Pretax Income | -145.99M |
| Net Income | -145.99M |
| EBITDA | -148.21M |
| EBIT | -150.18M |
| Loss Per Share | -$0.42 |
Full Income StatementBalance Sheet
The company has $533.73 million in cash and $216.98 million in debt, with a net cash position of $316.75 million or $0.91 per share.
| Cash & Cash Equivalents | 533.73M |
| Total Debt | 216.98M |
| Net Cash | 316.75M |
| Net Cash Per Share | $0.91 |
| Equity (Book Value) | 319.56M |
| Book Value Per Share | 0.92 |
| Working Capital | 512.01M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$125.73 million and capital expenditures -$330,000, giving a free cash flow of -$126.06 million.
| Operating Cash Flow | -125.73M |
| Capital Expenditures | -330,000 |
| Depreciation & Amortization | 1.97M |
| Net Borrowing | 197.38M |
| Free Cash Flow | -126.06M |
| FCF Per Share | -$0.36 |
Full Cash Flow StatementMargins
Gross margin is 90.78%, with operating and profit margins of -104.99% and -102.06%.
| Gross Margin | 90.78% |
| Operating Margin | -104.99% |
| Pretax Margin | -102.06% |
| Profit Margin | -102.06% |
| EBITDA Margin | -103.61% |
| EBIT Margin | -104.99% |
| FCF Margin | n/a |
Dividends & Yields
Nuvation Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.09% |
| Shareholder Yield | -15.09% |
| Earnings Yield | -8.88% |
| FCF Yield | -7.67% |
Analyst Forecast
The average price target for Nuvation Bio is $12.33, which is 161.23% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.33 |
| Price Target Difference | 161.23% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 51.42% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Nuvation Bio has an Altman Z-Score of 0.81 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.81 |
| Piotroski F-Score | 3 |
